Compare AHH & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AHH | NBP |
|---|---|---|
| Founded | 1979 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 532.2M | 503.8M |
| IPO Year | 2013 | 2020 |
| Metric | AHH | NBP |
|---|---|---|
| Price | $7.21 | $3.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $8.25 | ★ $9.00 |
| AVG Volume (30 Days) | 740.4K | ★ 760.5K |
| Earning Date | 02-16-2026 | 04-01-2026 |
| Dividend Yield | ★ 7.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $452,636,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.97 | N/A |
| P/E Ratio | $38.03 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.01 | $0.60 |
| 52 Week High | $9.70 | $6.79 |
| Indicator | AHH | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 61.40 | 41.80 |
| Support Level | $6.80 | $3.28 |
| Resistance Level | $7.12 | $3.52 |
| Average True Range (ATR) | 0.13 | 0.25 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 95.95 | 40.38 |
Armada Hoffler Properties Inc is a real estate company. It engages in developing, building, owning and managing the high-quality, institutional-grade office, retail, and multifamily properties in various markets throughout the Mid-Atlantic and Southeastern United States. It lease its properties under operating leases and recognize base rents. It also recognize revenue from tenant recoveries, through which tenants reimburses the company for expenses paid by them such as utilities, janitorial, repairs and maintenance. The company's operating segment includes office real estate, retail real estate, multifamily residential real estate, and general contracting, real estate financing and real estate services. It generates maximum revenue from the retail real estate segment.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.